Zimmer Biomet adds TMINI robotic system to portfolio By Investing.com

WARSAW, Ind. – Zimmer Biomet Holdings, Inc. (NYSE:), a global leader in medical technology, announced today an exclusive distribution agreement with THINK Surgical, Inc. for their TMINI Miniature Robotic System for total knee arthroplasty. This partnership is set to enhance Zimmer Biomet’s ROSA® Robotics suite, offering surgeons a handheld robotic option for knee surgeries.

The TMINI system is designed to facilitate accurate positioning of knee implants according to a preoperative CT-based plan. It represents a strategic expansion of Zimmer Biomet’s robotic offerings, following the introduction of ROSA Shoulder earlier this year, the first robotic system for shoulder replacement.

Dr. Nitin Goyal, Chief Science, Technology and Innovation Officer at Zimmer Biomet, highlighted the significance of the agreement: “We are proud to be the first medtech company to offer two complementary robotic systems for surgeons looking to incorporate robotic assistance while performing a knee replacement.”

The TMINI system is expected to be particularly beneficial for ambulatory surgery centers and other outpatient settings, due to its ergonomic, wireless design. It is anticipated to be available in select U.S. markets in the second half of 2024.

Zimmer Biomet’s partnership with THINK Surgical aims to accelerate the adoption of robotics in orthopedic surgery, indicating a continued investment in technological innovation within the medical field.

Zimmer Biomet, with a history of over 90 years, operates in more than 25 countries and sells in over 100, focusing on products and integrated digital and robotic technologies that improve patient care.

The information regarding the distribution agreement is based on a press release statement from Zimmer Biomet Holdings, Inc.

In other recent news, Zimmer Biomet Holdings Inc. has been maintaining a steady course, with several investment firms holding their ratings on the company. Piper Sandler and RBC Capital both maintained an Overweight and Outperform rating respectively, while Citi and Goldman Sachs reiterated their Neutral stance.

The ratings came after Zimmer Biomet’s investor day, where the company laid out its long-range plan for 2024 to 2027. The plan includes expectations of mid-single-digit revenue growth, increased bottom-line growth, and strategic mergers and acquisitions.

Zimmer Biomet also announced a strategic partnership with CBRE Group (NYSE:), Inc. to develop orthopedic ambulatory surgery centers across the U.S. The partnership aims to enhance medical technology accessibility and is part of Zimmer Biomet’s strategy to diversify into higher-growth markets.

The company’s board has also authorized a stock repurchase program of up to $2 billion, reflecting confidence in the firm’s financial health and commitment to shareholder value.

Analysts from Piper Sandler, RBC Capital, Citi, and Goldman Sachs expressed varying levels of confidence in Zimmer Biomet’s direction, with emphasis on the company’s aggressive push into the ambulatory surgical center space, the potential for revenue growth, and the importance of management execution.

InvestingPro Insights

As Zimmer Biomet Holdings, Inc. (NYSE:ZBH) forges ahead with its strategic partnership to enhance its ROSA® Robotics suite, the company’s financial health and market performance offer valuable insights for investors. Zimmer Biomet’s management has demonstrated confidence in the company’s future through aggressive share buybacks, signaling a strong belief in the company’s value. This is complemented by the company’s robust gross profit margin, which stood at an impressive 71.88% in the last twelve months as of Q1 2024, reflecting efficient operations and a solid competitive position in the medical technology market.

Investors may also find the company’s valuation metrics of interest. Zimmer Biomet currently trades at a P/E ratio of 24.3, with an adjusted P/E ratio of 19.36 for the last twelve months as of Q1 2024, which may be considered attractive relative to its near-term earnings growth. Additionally, the company’s PEG ratio for the same period is 0.21, suggesting that the stock could be undervalued based on its earnings growth projections.

It is noteworthy that analysts have revised their earnings expectations downwards for the upcoming period, which is an important consideration for potential investors. However, with a market capitalization of 23.22 billion USD and a consistent history of dividend payments for 13 consecutive years, Zimmer Biomet remains a significant player in its industry. The company also maintains a dividend yield of 0.85%, as of the last recorded date.

For those interested in a deeper dive into Zimmer Biomet’s potential, there are additional InvestingPro Tips available at https://www.investing.com/pro/ZBH. Readers can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking access to a suite of professional investment tools and insights. With 6 more tips available on InvestingPro, investors can gain a comprehensive understanding of Zimmer Biomet’s investment profile.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.